CG oncology

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates significantly on the bottom line, with a GAAP EPS loss of $0.90 vs. the $0.67 expected. While revenue of $1.16M notably exceeded the $0.36M consensus, R&D expenses surged to $54.7M due to intensified clinical trials. The company maintains a robust cash position of $1.0B, sufficient to fund operations through 2029, with critical Phase 3 topline data for PIVOT-006 and a BLA submission for cretostimogene expected by Q4 2026.